MAPS or Compass Pathways publishes Phase 3 psilocybin trial enrollment or safety data update

Two major psychedelic companies running government-approved depression trials must publicly share how their studies are going. This matters because it tells patients, doctors, and investors whether magic mushroom therapy actually works and is safe.

MAPS has ongoing Phase 3 psilocybin trials with breakthrough therapy designation, requiring periodic public disclosures to FDA and investors. Compass Pathways (COMP360) has already published Phase 3 data (2025) and may release follow-up analyses. Enrollment and safety updates are mandatory for breakthrough-designated trials and typically surface via ClinicalTrials.gov, press releases, or peer-reviewed publications. Six-month window makes at least one such disclosure highly probable. However, 'published' must mean a formal public document—not an internal update—to resolve YES.